Size Matters Less in Slovakia
Pharma companies in Slovakia are managing to circumvent the problems inherent in the size of the local market by focusing on the country’s advantages in market access and regional leadership,…
Why the J&J Takeover of Actelion Looks Unlikely
Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20…
Mapping Swiss Pharma
It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and…
France: A World Leader in Oncology
Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this…
Switzerland: Europe’s Brain
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
Switzerland: Europe's Brain
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
Czechia: A Regional Role Model?
One of the very first former-communist European states to attain a successful economic transition, the Czech Republic today puts across a compelling argument for being regarded as one of the…
Czech Republic: Entrepreneurial Spirit; Academic Legacy
Entrepreneurially-minded individuals, together with academic institutions with their fingers on the pulses of the latest trends, are propelling Czech pharma companies to great success and cementing the Czech Republic at…
Switzerland: A Hotbed of Innovation
Switzerland’s especially fine reputation for research impact and innovation generation is attracting a host of MNCs to base their European headquarters in the mountain nation and spend big on world-leading…
Hungary: A New Model of Care
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Pathways to Financing Innovation in Hungary
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have…
Company Profile / HUMAN BioPlazma: Hungaría Born and Bred
Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence…